ASLAN Pharmaceuticals Limited (ASLN)

ASLAN Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	21.25	56.9	90.17	14.32	22.2
Short-Term Investments	0	0	0	0.14	0
Cash & Cash Equivalents	21.25	56.9	90.17	14.46	22.2
Cash Growth	-62.65%	-36.89%	523.47%	-34.86%	-23.20%
Other Current Assets	2.88	3.98	3.61	1.04	0.07
Total Current Assets	24.13	60.88	93.78	15.5	22.27
Property, Plant & Equipment	0.26	0.29	0.23	0.48	0.77
Long-Term Investments	0.24	0.01	0.49	0	0.2
Goodwill and Intangibles	0	0.01	0.01	0	0
Other Long-Term Assets	0	0	0	0.1	0.11
Total Long-Term Assets	0.5	0.31	0.74	0.58	1.08
Total Assets	24.63	61.19	94.52	16.08	23.35
Accounts Payable	11	15.11	5.93	6.6	5.12
Current Debt	2.03	8.05	0.42	4.06	0.26
Other Current Liabilities	0.09	0	0	0	0
Total Current Liabilities	13.11	23.16	6.36	10.66	5.38
Long-Term Debt	24.8	29.66	30.86	15.46	18.38
Other Long-Term Liabilities	0	0	0	0.11	0.18
Total Long-Term Liabilities	24.8	29.66	30.86	15.58	18.57
Total Liabilities	37.91	52.82	37.21	26.23	23.95
Total Debt	26.83	37.71	31.28	19.52	18.65
Debt Growth	-28.87%	20.56%	60.23%	4.68%	33.45%
Retained Earnings	-321.07	-278.39	-227	-195.68	-179.48
Shareholders' Equity	-13.29	8.37	57.3	-10.45	-1.68
Net Cash / Debt	-5.57	19.19	58.89	-5.06	3.55
Net Cash / Debt Growth	-	-67.41%	-	-	-76.20%
Net Cash Per Share	-0.01	0.06	0.18	-0.03	0.02
Working Capital	11.02	37.71	87.42	4.84	16.89
Book Value Per Share	-0.81	0.60	4.40	-1.36	-0.26

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).